GlassScriptPhysician profile
Robert S Charles
NPI 1528008463
$2,933.88
in general payments reported to CMS, 2019-2025
27 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $570 · 2021: $762 · 2022: $155 · 2023: $256 · 2024: $202 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $482.39 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $389.32 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $384.95 | 2019-2023 | |
| Boston Scientific Corporation | $269.46 | 2019-2024 | Lithovue, Ams 700 |
| Janssen Biotech, INC. | $194.42 | 2019-2021 | |
| Myovant Sciences INC. | $127.79 | 2021-2022 | |
| Antares Pharma, INC. | $96.33 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $96.01 | 2020-2021 | |
| Pfizer INC. | $94.20 | 2019-2022 | |
| Medtronic, INC. | $90.96 | 2024-2025 | Interstim |
| Ferring Pharmaceuticals INC. | $89.42 | 2019 | |
| Abbvie INC. | $72.07 | 2022-2024 | |
| 180 Medical, INC. | $72.07 | 2019-2020 | |
| Mission Pharmacal Company | $65.85 | 2021-2024 | Uribel Tabs |
| Blue Earth Diagnostics | $63.76 | 2019-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.63 | 2020-2023 | Keytruda, Lynparza |
| Teleflex LLC | $45.44 | 2019-2021 | |
| Urovant Sciences INC | $44.03 | 2022 | |
| Ethicon US, LLC | $33.97 | 2020 | |
| Amgen INC. | $33.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.90 | 2024 | |
| Neotract INC. | $21.65 | 2020 | |
| Urogen Pharma, INC. | $21.53 | 2020 | |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Gemtesa |
| Endo Pharmaceuticals INC. | $15.20 | 2021 | |
| Dentsply Ih INC. | $13.02 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.